[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590480":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":18,"id":45,"slug":18,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":18,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":71,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Institut Claudius Regaud","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients with metastatic cancer","* Blood sample collection for circulating DP cell detection by flow cytometry and Cell Search analysis for the following patients:\n\n  * Cohort 1 : urothelial carcinoma\n  * Cohort 2 : renal carcinoma\n  * Cohort 3 : prostate adenocarcinoma\n  * Cohort 4 : upper aerodigestive tract carcinoma\n  * Cohort 5 : cervical carcinoma\n  * Cohort 6 : adenocarcinoma of endometrium\n* Blood sample collection for circulating DP cell detection by flow cytometry and Parsotix analysis for the following patients:\n\n  * Cohort 7 : cutaneous melanoma\n  * Cohort 8 : soft tissue sarcoma\n  * Cohort 9 : seminomatous and nonseminomatous germ cell tumors",[12],"Other: For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:","A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Thibaud VALENTIN, MD","CONTACT","0033 5 31 15 51 70","valentin.thibaud@iuct-oncopole.fr",[26],{"facility":27,"status":28,"city":29,"state":18,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Oncopole Claudius Regaud, IUCT-O","RECRUITING","Toulouse","31059","France","FR",{"type":34,"coordinates":35},"Point",[36,37],1.44367,43.60426,{"lat":37,"lon":36},[40,41],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},{"name":21,"role":42,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100590480",false,"NCT06967961","Research of Double-positive Circulating Cells (Tumor Marker \u002F CD45+) in Several Types of Metastatic Cancers","DP-PAN-CANCER","Inclusion Criteria:\n\n* 1\\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors\n* 2\\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet\n* 3\\. Age ≥ 18 years\n* 4\\. Patient affiliated to a French Social Security scheme\n* 5\\. Patient having signed his\u002Fher informed consent prior to inclusion in the study and prior to any specific procedure for the study.\n\nExclusion Criteria:\n\n* 1\\. Patient with localized disease.\n* 2\\. Pregnant or breast-feeding women.\n* 3\\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and\u002For procedures set out in the study protocol.\n* 4\\. Patient who has forfeited his\u002Fher freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).","ALL","18 Years",{"count":54,"type":55},450,"ESTIMATED","INTERVENTIONAL",[58],"NA","A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.\n\nEach patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.\n\n450 patients will be enrolled in total.",[61,62,63,64,65,66,67,68,69,70],"Urothelial Carcinoma","Renal Cancer","Prostate Adenocarcinoma","Adenocarcinoma of Endometrium","Cutaneous Melanoma","Soft Tissue Sarcoma (STS)","Nonseminomatous Germ Cell Tumor","Seminomatous Germ Cell Tumor","Upper Aerodigestive Tract Carcinoma","Cervical Carcinoma",[72,73,74],"metastatic cancers","Double Positive Circulating cells","liquid biopsy","2026-06-12",{"date":77,"type":78},"2026-06-15","ACTUAL",{"date":80,"type":78},"2025-07-23",{"date":82,"type":55},"2029-07-23",{"name":5,"class":6},1]